Patents by Inventor Evgenyi Shalaev

Evgenyi Shalaev has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NON-PROTEIN CLOSTRIDIAL TOXIN COMPOSITIONS
    Publication number: 20230355723
    Abstract: Pharmaceutical compositions that stabilize a Clostridial toxin active ingredient are described. The compositions can be liquid or solid compositions, and comprise a surfactant and an antioxidant. In some embodiments, the compositions comprise a surfactant selected from a poloxamer and a polysorbate; an antioxidant selected from methionine, N-acetyl cysteine, ethylenediaminetetraacetic acid and combinations thereof, and, optionally, a tonicity agent and/or a lyoprotector selected from, for example, trehalose, sucrose.
    Type: Application
    Filed: April 18, 2023
    Publication date: November 9, 2023
    Inventors: Maurice Abiad, Bhas Dani, Evgenyi Shalaev
  • NON-PROTEIN CLOSTRIDIAL TOXIN COMPOSITIONS
    Publication number: 20230355724
    Abstract: Pharmaceutical compositions that stabilize a Clostridial toxin active ingredient are described. The compositions can be liquid or solid compositions, and comprise a surfactant and an antioxidant. In some embodiments, the compositions comprise a surfactant selected from a poloxamer and a polysorbate; an antioxidant selected from methionine, N-acetyl cysteine, ethylenediaminetetraacetic acid and combinations thereof, and, optionally, a tonicity agent and/or a lyoprotector selected from, for example, trehalose, sucrose.
    Type: Application
    Filed: April 18, 2023
    Publication date: November 9, 2023
    Inventors: Maurice Abiad, Bhas Dani, Evgenyi Shalaev
  • NON-PROTEIN CLOSTRIDIAL TOXIN COMPOSITIONS
    Publication number: 20230173041
    Abstract: Pharmaceutical compositions that stabilize a Clostridial toxin active ingredient are described. The compositions can be liquid or solid compositions, and comprise a surfactant and an antioxidant. In some embodiments, the compositions comprise a surfactant selected from a poloxamer and a polysorbate; an antioxidant selected from methionine, N-acetyl cysteine, ethylenediaminetetraacetic acid and combinations thereof; and, optionally, a tonicity agent and/or a lyoprotector selected from, for example, trehalose and sucrose.
    Type: Application
    Filed: July 1, 2022
    Publication date: June 8, 2023
    Inventors: Maurice Abiad, Bhas Dani, Evgenyi Shalaev
  • NON-PROTEIN CLOSTRIDIAL TOXIN COMPOSITIONS
    Publication number: 20210369821
    Abstract: Pharmaceutical compositions that stabilize a Clostridial toxin active ingredient are described. The compositions can be liquid or solid compositions, and comprise a surfactant and an antioxidant. In some embodiments, the compositions comprise a surfactant selected from a poloxamer and a polysorbate; an antioxidant selected from methionine, N-acetyl cysteine, ethylenediaminetetraacetic acid and combinations thereof, and, optionally, a tonicity agent and/or a lyoprotector selected from, for example, trehalose, sucrose.
    Type: Application
    Filed: May 17, 2021
    Publication date: December 2, 2021
    Inventors: Maurice Abiad, Bhas Dani, Evgenyi Shalaev
  • NON-PROTEIN CLOSTRIDIAL TOXIN COMPOSITIONS
    Publication number: 20210290739
    Abstract: Pharmaceutical compositions that stabilize a Clostridial toxin active ingredient are described. The compositions can be liquid or solid compositions, and comprise a surfactant and an antioxidant. In some embodiments, the compositions comprise a surfactant selected from a poloxamer and a polysorbate; an antioxidant selected from methionine, N-acetyl cysteine, ethylenediaminetetraacetic acid and combinations thereof, and, optionally, a tonicity agent and/or a lyoprotector selected from, for example, trehalose, sucrose.
    Type: Application
    Filed: February 25, 2021
    Publication date: September 23, 2021
    Inventors: Maurice Abiad, Bhas Dani, Evgenyi Shalaev
  • Non-protein clostridial toxin compositions
    Patent number: 10973890
    Abstract: Pharmaceutical compositions that stabilize a Clostridial toxin active ingredient are described. The compositions can be liquid or solid compositions, and comprise a surfactant and an antioxidant. In some embodiments, the compositions comprise a surfactant selected from a poloxamer and a polysorbate; an antioxidant selected from methionine, N-acetyl cysteine, ethylenediaminetetraacetic acid and combinations thereof, and, optionally, a tonicity agent and/or a lyoprotector selected from, for example, trehalose, sucrose.
    Type: Grant
    Filed: August 5, 2019
    Date of Patent: April 13, 2021
    Assignee: Allergan, Inc.
    Inventors: Maurice Abiad, Bhas Dani, Evgenyi Shalaev
  • Solid complex, preparations and uses thereof
    Patent number: 10765629
    Abstract: Described herein is a solid complex comprising (Z)-7-((1R,2R,3R,5S)-2-((S,E)-5-(2,5-dichlorothiophen-3-yl)-3-hydroxypent-1-en-1-yl)-3,5-dihydroxycyclopentyl)hept-5-enamide (hereinafter “Compound 1”) and ?-cyclodextrin, and preparations and uses thereof. Also described herein are certain solid forms, preparations and uses thereof.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: September 8, 2020
    Assignee: ALLERGAN, INC.
    Inventors: Ke Wu, Evgenyi Shalaev, Prem Swaroop Mohanty, Jinping Wan
  • SOLID COMPLEX, PREPARATIONS AND USES THEREOF
    Publication number: 20200170941
    Abstract: Described herein is a solid comprising (Z)-7-((1R,2R,3R,5S)-2-((S,E)-5-(2,5-dichlorothiophen-3-yl)-3-hydroxypent-1-en-1-yl)-3,5-dihydroxycyclopentyl)hept-5-enamide (hereinafter “Compound 1”) and ?-cyclodextrin, and preparations and uses thereof. Also described herein are certain solid forms, preparations and uses thereof.
    Type: Application
    Filed: July 24, 2018
    Publication date: June 4, 2020
    Inventors: Ke Wu, Evgenyi Shalaev, Prem Swaroop Mohanty, Jinping Wan
  • NON-PROTEIN CLOSTRIDIAL TOXIN COMPOSITIONS
    Publication number: 20190351034
    Abstract: Pharmaceutical compositions that stabilize a Clostridial toxin active ingredient are described. The compositions can be liquid or solid compositions, and comprise a surfactant and an antioxidant. In some embodiments, the compositions comprise a surfactant selected from a poloxamer and a polysorbate; an antioxidant selected from methionine, N-acetyl cysteine, ethylenediaminetetraacetic acid and combinations thereof, and, optionally, a tonicity agent and/or a lyoprotector selected from, for example, trehalose, sucrose.
    Type: Application
    Filed: August 5, 2019
    Publication date: November 21, 2019
    Inventors: Maurice Abiad, Bhas Dani, Evgenyi Shalaev
  • NON-PROTEIN CLOSTRIDIAL TOXIN COMPOSITIONS
    Publication number: 20190247476
    Abstract: Pharmaceutical compositions that stabilize a Clostridial toxin active ingredient are described. The compositions can be liquid or solid compositions, and comprise a surfactant and an antioxidant. In some embodiments, the compositions comprise a surfactant selected from a poloxamer and a polysorbate; an antioxidant selected from methionine, N-acetyl cysteine, ethylenediaminetetraacetic acid and combinations thereof; and, optionally, a tonicity agent and/or a lyoprotector selected from, for example, trehalose and sucrose.
    Type: Application
    Filed: September 13, 2017
    Publication date: August 15, 2019
    Applicant: Allergan, Inc.
    Inventors: Maurice Abiad, Bhas Dani, Evgenyi Shalaev
  • Non-protein clostridial toxin compositions
    Patent number: 10369190
    Abstract: Pharmaceutical compositions that stabilize a Clostridial toxin active ingredient are described. The compositions can be liquid or solid compositions, and comprise a surfactant and an antioxidant. In some embodiments, the compositions comprise a surfactant selected from a poloxamer and a polysorbate; an antioxidant selected from methionine, N-acetyl cysteine, ethylenediaminetetraacetic acid and combinations thereof, and, optionally, a tonicity agent and/or a lyoprotector selected from, for example, trehalose, sucrose.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: August 6, 2019
    Assignee: Allergan, Inc.
    Inventors: Maurice Abiad, Bhas Dani, Evgenyi Shalaev
  • Process for annealing amorphous atorvastatin
    Patent number: 9932307
    Abstract: Processes for annealing amorphous atorvastatin is described. Pharmaceutical compositions and formulations containing annealed amorphous atorvastatin are also described.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: April 3, 2018
    Assignee: Pfizer Inc.
    Inventors: Renuka Devi Reddy, Evgenyi Shalaev, Ravi Mysore Shanker, Carl Bernard Ziegler
  • NON-PROTEIN CLOSTRIDIAL TOXIN COMPOSITIONS
    Publication number: 20180071361
    Abstract: Pharmaceutical compositions that stabilize a Clostridial toxin active ingredient are described. The compositions can be liquid or solid compositions, and comprise a surfactant and an antioxidant. In some embodiments, the compositions comprise a surfactant selected from a poloxamer and a polysorbate; an antioxidant selected from methionine, N-acetyl cysteine, ethylenediaminetetraacetic acid and combinations thereof, and, optionally, a tonicity agent and/or a lyoprotector selected from, for example, trehalose, sucrose.
    Type: Application
    Filed: September 13, 2017
    Publication date: March 15, 2018
    Inventors: Maurice Abiad, Bhas Dani, Evgenyi Shalaev
  • Process For Annealing Amorphous Atorvastatin
    Publication number: 20160332965
    Abstract: Processes for annealing amorphous atorvastatin is described. Pharmaceutical compositions and formulations containing annealed amorphous atorvastatin are also described.
    Type: Application
    Filed: July 27, 2016
    Publication date: November 17, 2016
    Inventors: Renuka Devi Reddy, Evgenyi Shalaev, Ravi Mysore Shanker, Carl Bernard Ziegler
  • Process for annealing amorphous atorvastatin
    Patent number: 9428455
    Abstract: Processes for annealing amorphous atorvastatin is described. Pharmaceutical compositions and formulations containing annealed amorphous atorvastatin are also described.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: August 30, 2016
    Assignee: Pfizer Inc.
    Inventors: Renuka Devi Reddy, Evgenyi Shalaev, Ravi Mysore Shanker, Carl Bernard Ziegler
  • Process For Annealing Amorphous Atorvastatin
    Publication number: 20150274659
    Abstract: Processes for annealing amorphous atorvastatin is described. Pharmaceutical compositions and formulations containing annealed amorphous atorvastatin are also described.
    Type: Application
    Filed: April 16, 2015
    Publication date: October 1, 2015
    Inventors: Renuka Devi Reddy, Evgenyi Shalaev, Ravi Mysore Shanker, Carl Bernard Ziegler
  • Process for forming amorphous atorvastatin
    Patent number: 9056831
    Abstract: A process for forming amorphous atorvastatin comprising the steps of dissolving atorvastatin in a non-hydroxylic solvent and removing the solvent by freeze-drying, as well as processes of dissolving atorvastatin in a hydroxylic solvent with a solubilizing agent or an alkalizing agent or an antioxidant and removing the solvent by freeze-drying to afford amorphous atorvastatin.
    Type: Grant
    Filed: February 8, 2014
    Date of Patent: June 16, 2015
    Assignee: Pfizer Inc.
    Inventors: Antone John deBettencourt, III, Peter Robert Rose, Evgenyi Shalaev, George Joseph Quallich, Carl Bernard Ziegler
  • Process for annealing amorphous atorvastatin
    Patent number: 9034913
    Abstract: Processes for annealing amorphous atorvastatin is described. Pharmaceutical compositions and formulations containing annealed amorphous atorvastatin are also described.
    Type: Grant
    Filed: September 11, 2006
    Date of Patent: May 19, 2015
    Assignee: Pfizer Inc.
    Inventors: Renuka D. Reddy, Evgenyi Shalaev, Ravi M. Shanker, Carl B. Ziegler
  • Process for Forming Amorphous Atorvastatin
    Publication number: 20140155627
    Abstract: A process for forming amorphous atorvastatin comprising the steps of dissolving atorvastatin in a non-hydroxylic solvent and removing the solvent by freeze-drying, as well as processes of dissolving atorvastatin in a hydroxylic solvent with a solubilizing agent or an alkalizing agent or an antioxidant and removing the solvent by freeze-drying to afford amorphous atorvastatin.
    Type: Application
    Filed: February 8, 2014
    Publication date: June 5, 2014
    Applicant: Pfizer Inc.
    Inventors: Antone John deBettencourt, III, Peter Robert Rose, Evgenyi Shalaev, George Joseph Quallich, Carl Bernard Ziegler
  • Process for forming amorphous atorvastatin
    Patent number: 8686163
    Abstract: A process for forming amorphous atorvastatin comprising the steps of dissolving atorvastatin in a non-hydroxylic solvent and removing the solvent by freeze-drying, as well as processes of dissolving atorvastatin in a hydroxylic solvent with a solubilizing agent or an alkalizing agent or an antioxidant and removing the solvent by freeze-drying to afford amorphous atorvastatin.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: April 1, 2014
    Assignee: Pfizer Inc.
    Inventors: Antone J deBettencourt, III, Evgenyi Shalaev, George J. Quallich, Carl B. Ziegler, Jr.